Since the MEK/ERK and AKT/mTOR pathways regulate the key metabolic process in carcinogenesis, approaches targeting the circCYP24A1/miR-421/CMTM4 pathway may become a promising treatment strategy in RCC. The gene discussed is MTOR; the disease is renal cell carcinoma.